Background: Treatment with immune checkpoint inhibitors (ICPi) has greatly improved survival for patients with advanced melanoma in recent years. Anti-CTLA-4 and anti-PD1 antibodies have been approved following large Phase III trials. Immunerelated neurological toxicity of varying severity has been reported in the literature. The cumulative incidence of neurotoxicity among ipilimumab, nivolumab and pembrolizumab is reported as <1% in published clinical trials. We aimed to identify the incidence of neurotoxicity in our institution across anti-CTLA4 and anti-PD-1 antibodies, including the combination of ipilimumab with nivolumab. We also review the existing literature and propose an investigation and management algorithm.
Introduction
Recent therapeutic advances have substantially improved the prognosis of advanced melanoma. Ipilimumab, nivolumab and pembrolizumab, monoclonal antibodies directed against immune checkpoints, are all approved for treatment and have substantially improved survival outcomes over cytotoxic therapies [1] [2] [3] [4] . Nivolumab may be combined with ipilimumab, resulting in the highest response rate and longest progression free survival (PFS) compared to monotherapy with either agent [5] . Ipilimumab also improves recurrence-free survival when used in the adjuvant setting [6] .
Toxicity from ICPi occurs due to both upregulation of the immune system and interference with self-tolerance. Rates of moderate and severe immune-related adverse events (irAEs) range from 10% to 15% for nivolumab and pembrolizumab, 20-30% for ipilimumab and 55% for the combination of ipilimumab and nivolumab (ipi þ nivo) [5, 7] . Frequently occurring irAEs include dermatitis, colitis, hepatitis, thyroid dysfunction and hypophysitis. Reassuringly, the vast majority of toxicity is reversible with corticosteroids and other immune-modulating medication (IMM). Neurological irAEs are rare, occurring in <1% patients treated in large clinical trials [1] [2] [3] [5] [6] [7] . To date, there is limited data available on the incidence of neurotoxicity outside reported clinical trials and most descriptions are contained within anecdotal case reports (see supplementary Table S1 , available at Annals of Oncology online). Neurological toxicity was not reported in the Checkmate-067 trial [5] and no cases in the literature have been attributed to ipi þ nivo yet. The best approach to its management is not defined.
We aimed to review our population of ICPi treated patients with advanced melanoma and identify the frequency of neurological irAEs across all ICPi therapies. We provide vignettes of complex case presentations and their treatment, as well as a proposed algorithm for management, in addition to a review of the available literature.
Methods
We identified all patients with advanced melanoma treated with ipilimumab, nivolumab, pembrolizumab, or ipi þ nivo, managed at the Royal Marsden Hospital between September 2010 and December 2015. This included patients on published clinical trials. The medical records for each patient were reviewed and neurological symptoms attributed to ICPi therapy were noted. Where patients had brain or leptomeningeal metastases and a neurological change or decline consistent with this on treatment, we did not record such episodes as drug-related neurological toxicity. Severity was graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Information on symptoms, pre-existing neurological or autoimmune conditions, investigations, treatment, need for admission and resolution of symptoms was collected. Descriptive statistics were used to analyse the data while the Kaplan-Meier method was used to summarize the overall survival estimates from initiation of treatment to death of any cause. Response to treatment by RECIST version 1.1 was documented in those affected by neurotoxicity. Time to RECIST progression and time to treatment failure (defined as time to next line of therapy or death) were also calculated for the patients with neurotoxicity. A systematic search strategy was performed on Pubmed using the terms 'ipilimumab', 'nivolumab' or 'pembrolizumab' and 'neurological', 'neuropathy', 'neurotoxicity', 'nervous', 'neuritis', 'meningitis', 'encephalitis', 'encephalopathy' to identify published cases and case series.
Results
There were 352 patients with melanoma who were treated with one or more ICPi from September 2010 until December 2015. In total, there were 413 treatment episodes (i.e. 61 patients received more than one ICPi). The majority were male (197; 56%) and the median age of the total population was 59 years. Median followup in our cohort was 26.7 months (IQR: 13.9-37.9 months). Ten episodes of immune-related neurological toxicity were recorded (10/413 treatment episodes, 2.4%; 10/352 patients, 2.8%), ranging from grade 1 to grade 4, and none recurring in the same patient. About 3 of the 10 cases were attributed to ipi þ nivo. Ten patients treated on the Checkmate-067 trial [5] remain blinded to therapy. See Table 1 for frequency by type of ICPi and grade.
Of these 10 cases, median age was 67 years (range 51-83), 4 were male. About 4 of 10 occurred during first-line treatment. Predominantly, peripheral nervous system disorders were identified (7/10), of which four were grade 3 or 4. About 2 of the 10 patients required a prolonged inpatient admission >3 months. Corticosteroid therapy was initiated in 5 of the 10 cases, and 3 cases were steroid-responsive. Seven patients made a full recovery, the time to which ranged from 7 to 29 weeks (median 9.4 weeks). Three patients did not have complete resolution of toxicity at the time of this review. Table 2 summarizes the clinical details of these 10 cases, the investigations performed and treatment.
In 7 of the 10 patients with neurotoxicity, an objective response was noted: 5 with partial response (PR) and 2 with complete response (CR). About 6 of the10 patients had progressed at the time of this review. The median duration of response was 13.1 months (range 1.0-25.9). Five patients commenced another drug treatment with a median time to treatment failure of 2.9 months (range 1.7-41.0). Several patients meeting criteria for RECIST PD did not require another line of treatment for several months. The median overall survival of patients experiencing neurotoxicity was greater than in the patients who did not develop neurotoxicity: 45.7 months (IQR 45.7-45.7 m) 
Case 1 vignette
A 78-year-old male commenced ipilimumab (3 mg/kg) as firstline treatment. One week following the fourth infusion, he presented with subacute right leg weakness developing over 1 week and impaired sensation of the plantar surface of his feet. Neurological examination revealed moderate weakness in extension and flexion of the hips and knees, dysaesthesia of hands and feet and areflexia of the triceps, knees and ankles. Examination of the CSF revealed raised protein at 0.74 g/l, no lymphocytes, normal glucose. MRI of the brain and spine were unremarkable. The patient was admitted for IV steroids with a provisional diagnosis of ipilimumab-related lumbosacral plexopathy. Following 24 h of twice daily 8 mg IV dexamethasone, he deteriorated. The patient was converted to 2 mg/kg IV methylprednisolone and transferred to a tertiary neurology centre. A diagnosis of acute sensorimotor polyradiculoneuropathy (a Guillain-Barrelike syndrome) was made. Motor nerve conduction studies demonstrated proximal demyelinating features but sensory studies were normal. Electromyography demonstrated a mildly reduced interference pattern only. Plasmapheresis was conducted on day 5 following his presentation due to a lack of clinical improvement with intravenous steroids (discontinued at this point due to plateau in neurological status). However, dysarthria and dysphagia developed within a week of completing plasmapheresis and nasogastric feeding was commenced. At his nadir, 4 weeks after onset, he was paraplegic and had limited use of his arms. Methylprednisolone 1 mg/kg was reinstituted and weaned over 2 months. The neuropathy stabilized over the fifth week after symptom onset. This patient's clinical course was characterized by repeat episodes of pneumonia necessitating ventilation and then a weaning tracheostomy. Re-imaging showed a PR. After 3 months, he regained some power in his legs. Five months from onset the patient's steroids (weaned down to 5 mg oral prednisolone 3 months from presentation) were ceased and he was discharged to a neurorehabilitation facility and demonstrates slow, ongoing improvement.
Case 2 vignette
A 79-year-old woman with a past medical history of Graves' disease commenced second-line nivolumab (3 mg/kg). She had been treated with ipilimumab 5 months prior and developed grade 3 colitis after cycle 1 requiring 3 months of glucocorticoid therapy and cessation of treatment. One week following cycle 4 nivolumab she presented with malaise and exertional dyspnoea. A comprehensive cardio-respiratory work-up was normal. One week after cycle 5 was due she re-presented with worsening dyspnoea and type 1 respiratory failure. Concurrent dysphagia was managed with nasogastric feeding. Pulmonary function testing revealed paradoxical abdominal motion in addition to low nasal sniff pressures (13 cm H 2 O), attributed to inspiratory muscle weakness. IV methylprednisolone was commenced at 1.5 mg/kg daily and in the absence of improvement she was moved to a critical care unit for noninvasive ventilation (NIV) 5 days later.
Neurological examination revealed fatiguable muscle weakness in the limbs with bulbar dysfunction. Given the similarities with a myasthenic syndrome and lack of improvement with 5 days of methylprednisolone, empirical pyridostigmine was initiated. However, a Tensilon test, acetylcholine receptor and neurological paraneoplastic antibodies were negative, as were electromyography and nerve conduction studies (including repetitive nerve stimulation). The working diagnosis was that of nivolumabinduced immune-related phrenic neuropathy resulting in diaphragmatic weakness and a bulbar palsy. After 2 weeks, IV immunoglobulin (IVIg) was commenced due to a plateau in symptoms and the patient clinically improved over the next couple of weeks. IV steroid was switched to oral and the patient was transferred to a specialized respiratory neurorehabilitation centre a month later. She was discharged home, off all corticosteroids, 4 months following initial presentation, and full resolution of symptoms occurred 1 month later. Surveillance imaging demonstrates no new measurable disease at 54-month post-treatment initiation.
Case 3 vignette
A 67-year-old male was commenced on combination ipilimumab (3 mg/kg) and nivolumab (1 mg/kg). Two weeks into cycle 1 he was admitted to hospital with new lower back pain associated with paraesthesia of his thighs, constipation, a grade 3 ALT derangement and progressive rash. On examination, the lower limbs had reduced power in hip flexion, absent knee but brisk ankle reflexes, and normal plantar responses. Symmetrical loss of fine touch and pain was demonstrated in the T10-L2 dermatomes bilaterally. The patient was commenced on 2 mg/kg IV methylprednisolone.
After 48 h, the left-sided thoracic sensory deficits progressed. Specialist neurology input was sought and a diagnosis of autoimmune bilateral lumbar plexopathy was made, though this did not account for the thoracic-level paraesthesia for which possible transverse myelitis was considered. MRI of the brain and spine were normal however. CSF analysis revealed elevated protein 1.26 g/l, lymphocytes and mononuclear cells were noted (white blood cell count: <1 mm 3 ). Matching oligoclonal bands (IgG) were found in the paired serum and CSF samples. Nerve conduction studies were normal. Autoimmune, vasculitis and bloodborne virus screens were normal. On the fifth day, there was a substantial improvement in the patient's mobility and sensory deficits, in addition to reduction in the ALT to grade 2, and methylprednisolone was converted to oral prednisolone.
Following intense input from physiotherapy and occupational therapy, he was fit for discharge on a reducing dose of prednisolone. At 2 months, his neurological symptoms had resolved. Prednisolone was weaned, however, the patient has required ongoing low-dose steroids to manage fevers complicating his nextline BRAF-targeted therapy. Surveillance imaging 1 month following treatment demonstrated an excellent PR to combination immunotherapy. Imaging at 2 months however indicated disease progression.
Discussion
Although ICPi have revolutionized the treatment of melanoma, they have given rise to a novel set of adverse effects that require early recognition, appropriate investigation and prompt, careful management. This is the first systematically reported, singleinstitution series of neurotoxicity across all ICPi treatments in melanoma, including the combination of ipilimumab with nivolumab. We report an overall immune-related neurotoxicity rate of 2.4%, over twice that reported in large phase III clinical trials [1] [2] [3] [5] [6] [7] . In particular, 14% of patients treated with combination ipilimumab and nivolumab developed a neurological irAE and all of these cases had another concurrent irAE. Despite a median time to symptom resolution of 9.4 weeks in our cohort (noting that some did not resolve), the median survival for this group is very long (45.7 months, CI 13.8-NE) and 70% of patients with neurotoxicity experienced an objective response, durable in 40%. This justifies intensive care and support in the acute treatment and rehabilitation of neurotoxicity in this group of patients.
Two series report immune-related neurotoxicity in 1.5% (11/ 752) of ipilimumab-treated patients [8] and 3.2% (16/496) of anti-PD-1 treated patients [9] , rates similar to our cohort (1% and 3%, respectively). Dysgeusia was included in these series (2/ 11 ipilimumab cases and 1/16 anti-PD-1). We have also summarized the published cases of neurological sequelae secondary to ICPi in advanced melanoma in supplementary Table S1 , available at Annals of Oncology online. Peripheral neuropathy, Guillain-Barre-like syndromes, cranial nerve palsies, demyelination and myasthenia gravis-type syndromes are all recognized adverse effects [10-12]. There is a bias in the literature towards reporting of neurotoxicity with ipilimumab, likely reflecting its earlier availability. Overall, the incidence of irAEs associated with ipilimumab is greater in comparison with anti-PD-1 monotherapy [5, 7] . However, in our series and that of Zimmer et al. [9] , this does not seem to be the case for neurological toxicity. As anti-PD-1 treatment is continued for a longer duration, there is arguably a greater chance of developing neurological sequelae at a late stage.
Our report presents several cases of neurological toxicity that do not neatly fit the characteristics of 'typical' neurological syndromes, such as in case vignette 3 where the lumbar plexopathy could not account for subjective thoracic sensory changes, and the bilateral phrenic nerve palsy in case vignette 2 associated with bulbar dysfunction. Both peripheral and central nervous systems may be affected and there does not appear to be a clear predominance of one over the other, although in our cohort the peripheral nervous system was more commonly impacted (70% versus 30% cases).
There is a risk of neurological irAEs at any stage throughout the course of treatment with immune-checkpoint agents, however presentations within the first 4 months predominated in our cohort (8/10, 80%). The existing series of ipilimumab and anti-PD-1 neurotoxicity also confirm the predominance of early presentations with only 27% (3/11) patients in the ipilimumab series [8] developing neurological toxicity after 4 months and 25% (4/ 16) in the anti-PD-1 series [9] .
Generally, the majority of irAEs can be effectively reversed with corticosteroids and, in keeping with this, it appears that most neurological toxicity is also steroid-responsive (three of five steroid-treated cases in our cohort). However, not all of our patients with neurotoxicity had a clear response to steroids (e.g. case vignettes 1 and 2) and alternative treatments such as IVIg and plasmapheresis may need to be employed in situations with an antibody-mediated pathogenesis. The area of greatest contention with the use of steroids is in Guillain-Barre-like syndromes where corticosteroids in cases of idiopathic onset are not beneficial (but have not been shown to be harmful), but plasma exchange or IVIg initiated within 2 weeks of onset can improve recovery time [13, 14] . It is important to note that allied health practitioners played significant roles in the recovery of neurotoxicity patients managed at our institution. We propose a comprehensive investigation and treatment algorithm ( Figure 1A-C) to aid clinicians in managing cases of immune-related toxicity.
Not all patients experience complete resolution of neurotoxicity. Three patients (30%) in our cohort had ongoing symptoms at the time of review. In the ipilimumab series by Voskens et al. [8] , 5/11 (45%) cases resolved, whereas only 6/16 (38%) cases resolved in the anti-PD-1 treated series by Zimmer et al. [9] . The individual duration of follow-up was not clear in these reports and given patients' recovery can take months, such figures may under-represent resolution rates. Looking at case reports is not reliable for such information as there is likely to be a bias towards positive outcomes. Like the immune-related endocrinopathies, neurotoxicity has the potential to cause permanent damage and disability. It should be specifically addressed in informed consent, especially in patients receiving combination ipi þ nivo where rates are potentially higher, and in patients receiving adjuvant ICPi therapy. This is particularly important as several patients in our series experienced durable responses and have lived for years.
Although the small numbers preclude any definitive statements, neurotoxicity may be a predictor of response. In our cohort, 70% had an objective response by RECIST criteria and many were durable. The objective response rate in the other reported series approximated that of the agents used: 2/11 treated with ipilimumab had a PR [8] and 8/16 had an objective response in the anti-PD-1 treated series [9] .
While there is very little data on the specific pathogenesis of immune checkpoint-related neurological toxicity, inflammation around endoneurial microvessels and sub-perineural oedema and inflammation may explain some presentations [15] . PD-1 is also expressed on B cells and blockade has been shown to enhance activation and proliferation [16] . Inhibition of CTLA-4 expressed on certain T helper and T regulatory cells may augment B cell responses and fail to suppress antibody responses [17] , thereby also predisposing to antibody-mediated disease.
Limitations
We acknowledge there are limitations within our retrospective review, mostly due to the small number of affected patients from which we cannot draw firm conclusions. Subtle (grade 1) changes may have been under-documented in the medical records. Our overall survival figures are calculated from the first immune checkpoint therapy and some patients may have had prior therapies such as BRAF inhibitors. Unlike the other reports, we did not record dysgeusia as a neurological toxicity. We made the assumption that neurological change occurring in the context of progressive central nervous system disease was not a toxicity per se. Ten patients' treatments remain blinded to the authors and therefore their data cannot fully contribute to our conclusions at the time of writing. Nonetheless, we feel our data contributes to the small body of literature on this important subject.
Conclusion
Immune-checkpoint inhibition is an established and effective treatment paradigm for patients with metastatic melanoma. As the use of these agents increases in other tumour types, it is important for clinicians to be aware of serious potential adverse effects, such as immune-related neurological toxicities, which may have lasting consequences. While these are rare and often responsive to steroid therapy, they can present in a number of patterns, often early in the course of treatment, and unfortunately resolution is not always seen. Thorough neurological examination and access to specialist investigations in order to classify and successfully treat these conditions is important, as many patients have a reasonable chance of long-term disease control. It is clear that further research is required to study the patterns of neurotoxicity, identify the underlying pathogenesis and to optimize the treatment paradigm. Development of an international database would be helpful to further refine management approaches in this complex area. Figure 1 . Continued
